Stoke Therapeutics/STOK

$11.97

2.13%
-
1D1W1MYTD1YMAX

About Stoke Therapeutics

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Ticker

STOK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Edward Kaye

Employees

110

Headquarters

Bedford, United States

STOK Metrics

BasicAdvanced
$628.5M
Market cap
-
P/E ratio
-$2.38
EPS
0.78
Beta
-
Dividend rate
$628.5M
0.78304
$16.40
$3.35
1.09M
6.987
-43.23%
-60.8%
-49.6%
71.574
3.514
3.939
-29.21%
8.52%

What the Analysts think about STOK

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 6 analysts.
97.74% upside
High $35.00
Low $17.00
$11.97
Current price
$23.67
Average price target

STOK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-960.71% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.8M
-15.15%
Net income
$-26.9M
9.8%
Profit margin
-960.71%
29.4%

STOK Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 4.76%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.53
-$0.69
-$0.55
-$0.60
-
Expected
-$0.70
-$0.64
-$0.63
-$0.63
-$0.61
Surprise
-23.88%
8.43%
-12.41%
-4.76%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Stoke Therapeutics stock?

Stoke Therapeutics (STOK) has a market cap of $628.5M as of April 18, 2024.

What is the P/E ratio for Stoke Therapeutics stock?

The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 0 as of April 18, 2024.

Does Stoke Therapeutics stock pay dividends?

No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next Stoke Therapeutics dividend payment date?

Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.

What is the beta indicator for Stoke Therapeutics?

Stoke Therapeutics (STOK) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Stoke Therapeutics stock price target?

The target price for Stoke Therapeutics (STOK) stock is $23.67, which is 97.74% above the current price of $11.97. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Stoke Therapeutics stock

Buy or sell Stoke Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing